VBI Vaccines (VBIV) received a Buy rating and a $9 price target from Oppenheimer analyst Leland Gershell today. The company’s shares closed yesterday at $1.77.
Gershell noted:
“We are initiating coverage on VBIV with an Outperform rating and a 12- to 18- month price target of $9. An innovator in the vaccine field, VBIV is advancing three candidates through clinical development for infection prevention (hepatitis B, CMV) and cancer treatment (glioblastoma). We see pivotal-stage hepB vaccine Sci-B-Vac as low risk, and its ability to protect less tractable populations should make it a niche competitor. The company’s eVLP technology is being leveraged for CMV (to enter Phase 2 in late 2019) as well as glioblastoma (in Phase 1/2). With a ~$160M EV and ample cash post a recent raise, we believe positive newsflow from any of VBIV’s programs could spark share appreciation.”
According to TipRanks.com, Gershell is a 1-star analyst with an average return of -4.7% and a 38.7% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Avenue Therapeutics Inc, Evofem Biosciences Inc, and AzurRx BioPharma Inc.
Currently, the analyst consensus on VBI Vaccines is a Moderate Buy with an average price target of $9.50.
See today’s analyst top recommended stocks >>
Based on VBI Vaccines’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $15.37 million. In comparison, last year the company had a GAAP net loss of $11.54 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
VBI Vaccines, Inc. is a biopharmaceutical company, which develops vaccines for infectious disease and immuno-oncology. Its pipeline includes Sci-B-Vac, CMV Vaccine, GBM Immunotherapy, MB Immunotherapy, and Zika Vaccine. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.